Does Radiotherapy in Unresectable Pancreatic Cancer Add Value?

Video

This video reviews the conflicting data and perspectives regarding the use of radiotherapy in unresectable pancreatic cancer.

In this video, John Ng, MD, of Weill Cornell Medical College in New York, reviews the conflicting data and perspectives regarding the use of radiotherapy in unresectable pancreatic cancer.

Ng gave a presentation on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content